As such, the pharmacological inhibition of TFF3 by the novel TFF3 inhibitor AMPC may potentially improve outcomes in the treatment of TFF3-positive CMS4 CRC, either as a single agent or in combination with conventional 5-FU. This evidence concerns the gene TFF3 and colorectal carcinoma.